All In Biotech

Drug Trial Radar · NCT01712789

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

682

Actual

Start

Nov 6, 2012

Primary completion

Dec 11, 2019

Study completion Dec 11, 2019

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years. In addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses. The exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.

Conditions

  • Multiple Myeloma

Interventions

  • PomalidomideDrug

    Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle

  • DexamethasoneDrug

    Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.

Locations

112 sites in 20 countries. Site status is shown where the registry gives one.

  • Medical University of Graz

    Graz, Austria

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria

  • Wilhelminenspital Vienna

    Vienna, Austria

  • Medical University of Vienna

    Vienna, Austria

  • AZ St-Jan Brugge Oostende AV

    Bruges, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • VUB Vrije Universiteit Brussel

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege

    Liège, Belgium

  • CHU Mont -Godinne

    Yvoir, Belgium

  • Aarhus University Hospital

    Aarhus, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Tartu University Hospital Clinic

    Tartu, Estonia

  • Helsingin yliopistollinen keskussairaala

    Helsinki, Finland

  • Turku University Hospital

    Turku, Finland

  • Centre Hospitalier de la cote basque

    Bayonne, France

  • Hopital Henri Mondor

    Créteil, France

  • Hopital A. Michallon

    La Tronche, France

  • CHRU Claude Huriez

    Lille, France

  • Institut Paoli Calmette Hematologie

    Marseille, France

  • CHU Hotel Dieu

    Nantes, France

  • Hopital Saint Antoine

    Paris, France

  • Service Hemato-Immunologie Hopital St Louis

    Paris, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • CHU de Reims

    Reims, France

  • Hematologie - CHU Purpan

    Toulouse, France

  • CHRU Hopital Bretonneau

    Tours, France

  • CHU Nancy Hematology

    Vandœuvre-lès-Nancy, France

  • Charite, Campus Benjamin Franklin Universitatsmedizin Berlin

    Berlin, Germany

  • Klinikum Chemnitz

    Chemnitz, Germany

  • Klinikum der Universitat zu Koln

    Cologne, Germany

  • Universitatsklinikum Carl Gustav Carus

    Dresden, Germany

  • Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie

    Düsseldorf, Germany

  • Universitatsklinikum Essen-

    Essen, Germany

  • Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik

    Freiburg im Breisgau, Germany

  • Abt Haematologie - Onkologie / Allg. Krankenhaus Altona

    Hamburg, Germany

  • Universitatsklinikum Heidelberg

    Heidelberg, Germany

  • Universitatsklinikum Jena

    Jena, Germany

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.